Ketorolac tromethamine 0.4% as a treatment for allergic conjuctivitis

Expert Opinion on Drug Metabolism and Toxicology

Volumn 4, Issue 4, 2008, Pages 507-511

  Schechter, Barry A ^a  

^a Florida Eye Microsurgical Institute   (United States)

Author keywords

Allergic conjunctivitis; Anti inflammatory; Dry eye; Ketorolac tromethamine

Indexed keywords

ACETYLSALICYLIC ACID; BROMFENAC; CYCLOSPORIN; KETOROLAC TROMETAMOL; NEPAFENAC; NONSTEROID ANTIINFLAMMATORY AGENT; PHENYLACETIC ACID; PLACEBO; STEROID;

ADJUVANT THERAPY; ALLERGIC CONJUNCTIVITIS; ANALGESIC ACTIVITY; ANTIINFLAMMATORY ACTIVITY; ANTIPYRETIC ACTIVITY; ARTICLE; CATARACT; CATARACT EXTRACTION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONJUNCTIVAL HYPEREMIA; CORNEA INJURY; DRUG CONTRAINDICATION; DRUG DOSE COMPARISON; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG FORMULATION; DRUG HYPERSENSITIVITY; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG STRUCTURE; DRUG TOLERABILITY; DRY EYE; EYE DISCOMFORT; EYE EDEMA; EYE INFLAMMATION; EYE PAIN; HUMAN; IMMUNE RESPONSE; INTRAOCULAR PRESSURE; KERATOMILEUSIS; LENS IMPLANT; MONOTHERAPY; NONHUMAN; PHACOEMULSIFICATION; PHOTOREFRACTIVE KERATECTOMY; POSTOPERATIVE PAIN; RISK REDUCTION; VISUAL ACUITY; VITRECTOMY; WOUND HEALING;

ANTI-ALLERGIC AGENTS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CLINICAL TRIALS AS TOPIC; CONJUNCTIVITIS, ALLERGIC; DRY EYE SYNDROMES; HUMANS; KETOROLAC TROMETHAMINE; OPHTHALMIC SOLUTIONS; TREATMENT OUTCOME;

ANIMALIA;

EID: 44349159558     PISSN: 17425255     EISSN: None     Source Type: Journal    
DOI: 10.1517/17425255.4.4.507     Document Type: Article

References (22)

1. Acular LS [Package insert]. Irvine, CA: Allergan Corporation; 2003
2. Bucci FA, Evans RE, Amico LM. Comparison of ketorolac 0.5%, ketorolac 0.4%, and diclofenac 0.1% combined with prednisolone 0.1% on aqueous flare following cataract surgery. Association for Research in Vision and Ophthalmology Annual Meeting; 2005 May 1-5; Fort Lauderdale, FL. Poster 789
3. Leonardi A, Busato F, Fregona I, et al. Anti-inflammatory and antiallergic effects of ketorolac tromethamine in the conjunctival provocation model. Br J Ophthalmol 2000;84:1228-32
4. Raizman MB. Results of a survey of patients with ocular allergy treated with topical ketorolac tromethamine. Clin Ther 1995;17:882-90
5. Ballas Z, Blumenthal M, Tinkelman DG, et al. Clinical evaluation of ketorolac tromethamine 0.5% ophthalmic solution for the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 1993;38:141-8
6. Waterbury LD, Flach AJ. Comparison of ketorolac tromethamine, diclofenac sodium, and loteprednol etabonate in an animal model of ocular inflammation. J Ocul Pharmacol Ther 2006;22:155-9
7. Woodward DF, Nieves AL, Frielaender MH. Characterization of receptor subtypes involved in prostanoid-Laduced conjunctival pruritis and their role in mediating allergic conjunctival itching. J Pharmacol Exp Ther 1996;279:137-42
8. Tinkelman DG, Rupp G, Kaufamn H, et al. Double-masked, paired comparison clinical study of ketorolac tromethamine 0.5% ophthalmic solution compared with placebo eyedrops in the treatment of seasonal allergic conjunctivitis. Surv Ophthalmol 1993;38:133-40
9. Solomon KD, Donnenfeld ED, Raizman M, et al. Safety and efficacy of ketorolac tromethamine 0.4% ophthalmic solution in post-photorefractive keratectomy patients. J Cataract Refract Surg 2004;30:1653-60
10. Donnenfeld ED, Holland EJ, Durrie DS, Raizman MB. Double-masked study of the effects of nepafenac 0.1% and ketorolac 0.4% on corneal epithelial wound healing and pain after photorefractive keratectomy. Adv Ther 2007;24:852-62
11. Trattler W, McDonald M. Double-masked comparison of ketorolac tromethamine 0.4% versus nepafenac sodium 0.1% for postoperative healing rates and pain control in eyes undergoing surface ablation. Cornea 2007;26:665-9
12. Busbee BG, JHeier JS, Waterbury D, et al. Comparison of vitreous PGE2 concentrations of ketorolac 0.4%, bromfenac 0.09%, and nepafenac O. 1% in patients undergoing vitrectomy. Association for Research in Vision and Ophthalmology Annual Meeting; 2007 May 6-10; Fort Lauderdale, FL
13. Schechter BA. Ketorolac during the induction phase of cyclosporine-A therapy. J Ocul Pharmacol Ther 2006;22:150-4
14. Sowka JW, Gurwood AS, Kabat AG. Handbook of Ocular Disease Management. 4th edition. New York: Jobson Medical Information; 2004
15. Rashi AI, Okada N, Satake Y, et al. The change of prostaglandins and cysteinyl-leukotriene concentrations in the tears of patients with severe allergic conjunctivitis. Association for Research in Vision and Ophthalmology Annual Meeting; 2007 May 6-10; Fort Lauderdale, FL
16. Majmudar PA. Allergic conjunctivitis. Available from: www.emedicine.com/ oph/TOPIC85.htm [Last accessed 25 October 2007]
17. McColgin AZ, Heier JS. Control of intraocular inflammation associated with cataract surgery. Curr Opin Ophthalmol 2000;11:3-6
18. Polansky JR, Weinreb RN. Steroids as anti-inflammatory agents. In: Pharmacology of the Eye. Sears ML, editor. New York: Springer-Verlag; 1984. p. 460-538
19. Sandoval HP, De Castro LE, Vroman DT, Solomon KD. Evaluation of 0.4% ketorolac tromethamine ophthalmic solution vs 0.5% ketorolac tromethamine ophthalmic solution after phacoemulsification and intraocular lens implantation. J Ocul Pharmacol Ther 2006;22:251-7
20. Goyal R, Shankar J, Fone DL, Hughes DS. Randomised controlled trial of ketorolac in the management of corneal abrasions. Acta Ophthalmol Scand 2001;79:177-9
21. Roberts CW. Comparison of the ocular comfort of acular LS with acular PF in healthy volunteers. Association for Research in Vision and Ophthalmology Annual Meeting; 2004 Apr 25-29; Fort Lauderdale, FL. Poster 4855
22. Fujishima H, Toda I, Shimazaki J, Tsubota K. Allergic conjunctivitis and dry eye. Br J Ophthalmol 1996:80:994-7